Idelalisib
| CAS No. | 870281-82-6 |
|---|---|
| MDL No. | MFCD19443647 |
| MF | C22H18FN7O |
| MW | 415.40 |
| InChI Key | IFSDAJWBUCMOAH-HNNXBMFYSA-N |
Pricing & Availability
| Pack Size | Purity | Price | Availability | Action |
|---|---|---|---|---|
| - | - | On Request | On Request | |
| Custom synthesis and bulk supply options are available upon request. | ||||
Product Information
Idelalisib is a quinazoline derivative, specifically 5-fluoro-3-phenylquinazolin-4-one with the hydrogen at position 2 replaced by a (1S)-1-(3H-purin-6-ylamino)propyl group. It is used to treat refractory indolent non-Hodgkin's lymphoma and relapsed chronic lymphocytic leukemia. It functions as an antineoplastic agent, apoptosis inducer, and inhibitor of phosphatidylinositol 3-kinase (EC 2.7.1.137). It belongs to the classes of purines, organofluorine compounds, quinazolines, aromatic amines, and secondary amino compounds.
| CAS No. | 870281-82-6 |
|---|---|
| Product Name | Idelalisib |
Biological Targets
PIK3CD
Associated Conditions
Hodgkins lymphoma·Mantle cell lymphoma·pancreatic ductal adenocarcinoma·follicular lymphoma·myelofibrosis·
* The information provided here is compiled from public sources and is for reference only.
